A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+Urothelial Carcinoma

PrintE-mail
Title A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+Urothelial Carcinoma
Contact EH
Principal Investigator Thomas Schwaab, MD
Study Number 217712
Phase2
Summary To evaluate overall survivor following administration of DN24-02.  Also to evaluate disease-free survival following administration of DN24-02.  It is anticipated that SOC for the control group will comprise observation only until documentation of disease recurrence.
Eligibility See ClinicalTrials.gov link for current Eligibility criteria.
For more information about the clinical study go to Clinicaltrial.Gov